The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

Olympian Clinical Research

FEBRUARY 26, 2021

Clinical trials are research studies designed to evaluate or test a medical, surgical, or behavioral intervention. Most recently, clinical trials have gained recognition through the development and testing of Covid-19 vaccines. Today we’re taking some time to highlight a few of the biggest ones!

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

The Pharma Data

MAY 15, 2023

Positive data from two Phase 3 Dupixent ® (dupilumab) trials in prurigo nodularis published in Nature Medicine Positive results from two Phase 3 Dupixent ® (dupilumab) trials in adults with uncontrolled prurigo nodularis have been published in Nature Medicine. Results from the trials were the basis for the U.S.

Medicine 40

Medicine Trials Dermatology FDA Approval 40

WCG Clinical

MAY 15, 2023

By harnessing patient insights on clinical research technology, data accuracy can be improved, the clinical trial process can be streamlined, and the burden on participants and sites can be reduced. Engaging with advocacy groups can also drive patient participation in trials. And keep in mind that not everyone owns a suitable device.

Clinical Research 52

Clinical Research Development Trials Research 52

BioTech 365

OCTOBER 28, 2020

NOT FOR DISTRIBUTION IN THE UK OR IRELAND − Results from a pooled safety analysis of three Phase 3 trials (ECZTRA 1, 2, and ECZTRA 3), Phase 2 (ECZTRA 5) and Phase 2b trials demonstrate overall frequency of AEs with … Continue reading →

Dermatology 40

Dermatology Trials Vaccination Vaccine 40

The Pharma Data

MARCH 29, 2022

The positive 12- and 52-week results from ELEVATE UC 52 follow the recent announcement of positive 12-week findings from the ELEVATE UC 12 trial on March 23. Etrasimod demonstrated a safety profile consistent with previous studies, including the Phase 2 OASIS trial.

Trials 52

Trials Dermatology Development Medicine 52

Drug Discovery World

APRIL 16, 2023

DDW’s Megan Thomas rounds up highlights from Sunday 16 April at AACR 2023, from promising trial results for a personalised mRNA-based cancer vaccine to winners of lifetime achievement awards.

Clinical Trials 52

Clinical Trials Clinical Trials Research Vaccination 52

XTalks

DECEMBER 20, 2023

The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy. The company’s COVID-19 vaccine Comirnaty and COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir) were the company’s top sellers that year. billion in 2022.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

Drug Discovery World

DECEMBER 16, 2022

An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. . mRNA cancer vaccine meets primary efficacy endpoint . Experimental immunotherapy has over 70% response rate . New dermatitis treatment shows promising long-term results .

Drugs 52

Drugs Vaccination Vaccine Genetics 52

The Pharma Data

MARCH 4, 2021

associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. Lymphopenia – Absolute lymphocyte count (ALC) <500 cells/mm 3 were reported in Olumiant clinical trials. 10x ULN were observed in patients in Olumiant clinical trials.

Trials 52

Trials Development Dermatology Clinical Trials 52

The Pharma Data

MARCH 13, 2022

Arena has previously indicated that it expected the results of the Phase 3 ELEVATE-UC trial of etrasimod in ulcerative colitis during the first quarter of 2022. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines.

Dermatology 52

Dermatology Cardiology Development Medicine 52

Delveinsight

AUGUST 25, 2021

The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, or relieve symptoms. billion followed by the other sectors such as Immunology, Hepatology, and Dermatology (USD 4.86

Vaccination 98

Vaccination Vaccine Sales Drugs 98

The Pharma Data

JANUARY 24, 2021

With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. Read on to see.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

AUGUST 9, 2021

Food and Drug Administration (FDA) approved SKYRIZI 150 mg in April based on data from three clinical trials showing the single-dose SKYRIZI 150 mg injection was bioequivalent, working the same as two injections of SKYRIZI 75 mg per dose with a consistent efficacy and safety profile. ” The U.S.

Bioequivalency 52

Bioequivalency Vaccination Vaccine Medicine 52

The Pharma Data

MARCH 23, 2022

The only large-scale prospective study in dermatology designed to generate key disease insights among Black, Hispanic, Asian, Indigenous and other people of color Study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities. Source link: [link].

Dermatology 52

Dermatology Clinical Research Research Medicine 52

pharmaphorum

SEPTEMBER 29, 2022

Dupixent (dupilumab) has been approved on the back of two phase 3 trials in patients with prurigo nodularis whose symptoms were inadequately controlled with current drugs. The suffering he notes from the #itch is 100… [link]. — Brian S. Kim (@itchdoctor) September 29, 2022.

Drugs 67

Drugs Immune Response Allergies Sales 67

WCG Clinical

APRIL 3, 2023

If we are able to tap into that, we can engage the participant not only during recruitment and enrollment, but throughout the entirety of the trial. A Proven Strategy When we focus on the participant’s perspective, we improve recruitment and retention and increase the likelihood of a successful trial. Use vendor resources?

Dermatology 52

Dermatology Trials Development Clinical Trials 52

XTalks

JUNE 14, 2021

Amazon’s contributions to COVID-19 pandemic efforts began early this year as the online retail giant wrote a letter to US President Biden offering operational, IT and communications support for COVID-19 vaccine distribution. Related: Google Launches AI-Based Dermatology Assist Tool.

Biohazard 59

Biohazard Biohazard Dermatology Clinical Trials 59

The Pharma Data

SEPTEMBER 15, 2020

Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. BNT162 mRNA-based Vaccine Program. Protease Inhibitor Program.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

JUNE 2, 2022

Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-1) Immune Modulators clinical trial, sponsored by the National Institutes of Health (NIH). Safety profile of Orencia remained consistent, with no new safety signals reported.

Clinical Trials 52

Clinical Trials Clinical Trials Dermatology Trials 52

pharmaphorum

JANUARY 5, 2021

Anyone who proposed that a novel, deadly virus would spread, with a vaccine developed demonstrating 95% efficacy, and approved for patients in less than a year would have been scoffed at. These changes are likely to reduce only slowly in the Vaccine+ environment, and will not be entirely reversed.

Sales 104

Sales Marketing Production Vaccination 104

The Pharma Data

APRIL 6, 2021

Lymphopenia – Absolute lymphocyte count (ALC) <500 cells/mm 3 were reported in Olumiant clinical trials. Anemia – Decreases in hemoglobin levels to <8 g/dL were reported in Olumiant clinical trials. 10x ULN were observed in patients in Olumiant clinical trials. VACCINATIONS : Avoid use of live vaccines with Olumiant.

Drugs 52

Drugs Dermatology Clinical Trials Clinical Trials 52

The Pharma Data

APRIL 28, 2021

PARIS – April 23, 2021 – New analyses from Dupixent ® (dupilumab) trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. Head of Global Development in Immunology and Inflammation at Sanofi. “

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

OCTOBER 26, 2020

The filings were based on the results of a robust Phase 3 clinical trial program, across which abrocitinib demonstrated statistically superior improvements in skin clearance, disease extent, and severity, as well as rapid improvements (measured as early as Week 2) in itch versus placebo. About Abrocitinib. Pfizer Inc.: Pfizer Inc.:

Clinical Trials 40

Clinical Trials Clinical Trials Trials Medicine 40

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. billion in 2022. for a pediatric dose.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

OCTOBER 28, 2022

XELJANZ has been studied in more than 50 clinical trials worldwide, including more than 20 trials in rheumatoid arthritis (RA) patients, and prescribed to more than 362,000 adult patients (the majority of whom were RA patients) worldwide since 2012. VACCINATIONS. Avoid use of live vaccines concurrently with XELJANZ.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Furthermore, Novartis joined industry-wide efforts to meet global demand for COVID-19 vaccines and therapeutics. Adakveo sales reached USD 37 million. Financials. First quarter.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

MAY 18, 2021

. “As the first biologic treatment for atopic dermatitis approved for this age group, DUPIXENT ® is a promising new option for treating children living with this chronic disease,” says Dr. Melinda Gooderham , Dermatologist and Medical Director at the SKiN Centre for Dermatology. About Sanofi.

Production 40

Production Dermatology Medicine Clinical Trials 40

The Pharma Data

APRIL 4, 2023

Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The approval is based on data from the KEYNOTE-869 trial (also known as EV-103) dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

The Pharma Data

JANUARY 26, 2021

Reddy’s”) and Global Response Aid FZCO (GRA) today announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Life Science 40

Life Science Production Marketing Dermatology 40

The Pharma Data

AUGUST 5, 2021

More information on this trial can be found at www.clinicaltrials.gov (NCT03738397). Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn’s disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing. 4 at week 16.

Medicine 52

Medicine Dermatology Bacteria Vaccination 52

The Pharma Data

APRIL 28, 2021

More information on these trials can be found at www.clinicaltrials.gov (KEEPsAKE-1: NCT03675308; KEEPsAKE-2: NCT03671148). Phase 3 trials of SKYRIZI in psoriasis, Crohn’s disease, ulcerative colitis and psoriatic arthritis are ongoing. have recently received or are scheduled to receive an immunization (vaccine).

Medicine 40

Medicine Trials Drugs Dermatology 40

The Pharma Data

FEBRUARY 22, 2021

More information on these trials can be found at www.clinicaltrials.gov (NCT03653026, NCT02819635, NCT03006068). Phase 3 trials of RINVOQ in ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn’s disease, atopic dermatitis and giant cell arteritis are ongoing. Available at: [link].

Medicine 52

Medicine Development Drugs Trials 52

The Pharma Data

JUNE 18, 2021

“In our global clinical trial program to-date, risankizumab has shown clinically meaningful rates of endoscopic response and clinical remission among patients living with moderate to severe Crohn’s disease,” said Michael Severino, M.D., 1 Both patients continued in the trial. vice chairman and president, AbbVie.

Trials 40

Trials Development Clinical Trials Clinical Trials 40